Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Clinitech Laboratory Ltd (544220)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544220 NSE: Hospital & Healthcare Services | Small Cap | Clinitech Laboratory Share Price
₹32 0.00 (0.00%)
As on 07-Oct'26 16:59
Clinitech Laboratory Ltd (544220)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544220 NSE: Hospital & Healthcare Services | Small Cap | Clinitech Laboratory Share Price
₹32 0.00 (0.00%)
As on 07-Oct'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹7 Cr.
Current Price
₹32
52-Week Low / High
₹29 / 47
TTM EPS
₹1.8
TTM Sales
₹9.5 Cr.
Book Value per Share
₹40.5
P/E Ratio
17.47
Lower than its 5-year historical median
Industry PE
86.8
Price to Book (P/B)
0.79
Lower than its 5-year historical median
Price to Sales (P/S)
0.77
Lower than its 5-year historical median
EV/EBITDA
4.88
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
4.59%
Return on Capital Employed (ROCE)
7.15%
Return on Assets (ROA)
3.83%
Operating Profit Margin
10.4%
Net Profit Margin
4.37%
Gross Profit Margin
11.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
15.19%
Operating Profit Growth (1 Year)
-
19.28%
Net Profit Growth (1 Year)
-
5.13%
Asset Quality
Promoter Holding
64.62%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹7 Cr.
Equity
₹2.3 Cr.
Face Value
₹10
All Time Low / High
₹28.55 / 120.75
Check Before You Invest
M-Cap below 100cr DeciZen not available
Is Clinitech Laboratory Ltd a good quality company?
Clinitech Laboratory Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Clinitech Laboratory Ltd performance compare with that of its Peers?
Revenue growth of Clinitech Laboratory Ltd vs industry peers?
Clinitech Laboratory Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of %, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Clinitech Laboratory Ltd?
Promoters hold 64.62% of the Clinitech Laboratory Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Clinitech Laboratory Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -20% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Clinitech Laboratory Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 32.5% | 32.6% | 30.4% | 15.3% | 9.2% | 7.3% | - |
| Value Creation Index ⓘ | 1.3 | 1.3 | 1.2 | 0.1 | -0.3 | -0.5 | - |
Growth Parameters ⓘ |
|||||||
| Sales ⓘ | 4.6 | 6.4 | 6.4 | 6.4 | 8.2 | 9.5 | 9 |
| Sales YoY Gr. | - | 40.2% | -0.5% | 0.8% | 28.6% | 15.2% | - |
| Adj EPS ⓘ | 2.7 | 3.4 | 4.1 | 2.2 | 1.5 | 1.9 | 1.9 |
| YoY Gr. | - | 27.6% | 19.6% | -47.2% | -29.6% | 21.7% | - |
| BVPS (₹) ⓘ | 9.3 | 12.3 | 15.9 | 21.1 | 38.7 | 40.5 | 40.5 |
| Adj Net Profit ⓘ | 0.4 | 0.5 | 0.6 | 0.4 | 0.4 | 0.4 | 0 |
| Cash Flow from Ops. ⓘ | 0.4 | 1 | 1.3 | -1.3 | -0.9 | -0.9 | - |
| Debt/CF from Ops. ⓘ | 1.4 | 0.9 | 0.8 | -0.7 | 0 | -0.4 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 15.8% | 14.3% | 15.2% | ||||
| Adj EPS ⓘ | NA | -7.1% | -23.2% | 21.7% | ||||
| BVPSⓘ | NA | 34.3% | 36.7% | 4.8% | ||||
| Share Price | - | - | - | -15.8% | ||||
Key Financial Parameters ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 28.9 | 31.7 | 29 | 12.3 | 5.6 | 4.7 | 4.6 |
| Op. Profit Mgn % ⓘ | 18.2 | 16.7 | 21.5 | 15.6 | 10.1 | 10.5 | NAN |
| Net Profit Mgn % ⓘ | 8.8 | 8 | 9.7 | 5.7 | 4.2 | 4.5 | 4.5 |
| Debt to Equity ⓘ | 0.4 | 0.5 | 0.4 | 0.2 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 74 | 71 | 91 | 142 | 188 | 0 |
| Cash Conv. Cycle ⓘ | 0 | -4 | -4 | 16 | 36 | 63 | 0 |
Valuation of Clinitech Laboratory - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Sales | 8.23 | 9.49 |
| Operating Expenses ⓘ + | 7.40 | 8.50 |
| Operating Profit ⓘ | 0.83 | 0.99 |
| Operating Profit Margin (%) | 10.1% | 10.4% |
| Other Income ⓘ + | 0.23 | 0.19 |
| Interest ⓘ | 0.06 | 0.07 |
| Depreciation ⓘ | 0.45 | 0.51 |
| Profit Before Tax ⓘ | 0.55 | 0.60 |
| Tax ⓘ | 0.16 | 0.18 |
| Profit After Tax | 0.39 | 0.41 |
| PAT Margin (%) | 4.8% | 4.4% |
| Adjusted EPS (₹) | 1.7 | 1.8 |
| Dividend Payout Ratio (%) | 0% | 0% |
| PARTICULARS | Mar'25 | Mar'26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 8.83 | 9.25 | |||||||||
| Debt + | 0 | 0.54 | |||||||||
| Minority Interest | 0 | 0 | |||||||||
| Trade Payables | 0.76 | 0.48 | |||||||||
| Others Liabilities ⓘ | 1.09 | 0.71 | |||||||||
| Total Liabilities ⓘ | 10.67 | 10.98 | |||||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 2.12 | 2.18 | |||||||||
| CWIP ⓘ | 1.01 | 1.25 | |||||||||
| Investments ⓘ | 0.07 | 0.07 | |||||||||
| Inventories | 0.53 | 0.73 | |||||||||
| Trade Receivables | 1.54 | 1.85 | |||||||||
| Cash Equivalents | 3.07 | 2.11 | |||||||||
| Others Assets ⓘ | 2.32 | 2.78 | |||||||||
| Total Assets ⓘ | 10.67 | 10.98 | |||||||||
| PARTICULARS | Mar'25 | Mar'26 |
|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -0.88 | -0.79 |
| Cash Flow From Investing Activity ⓘ + | -0.73 | -0.68 |
| Cash Flow From Financing Activity ⓘ + | 3.98 | 0.51 |
| Net Cash Flow ⓘ | 2.37 | -0.96 |
| PARTICULARS | Mar'25 | Mar'26 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 4.47 | 4.59 | ||||||||
| ROCE (%) | 6.91 | 7.15 | ||||||||
| Asset Turnover Ratio | 0.77 | 0.88 | ||||||||
| PAT to CFO Conversion(x) | -2.26 | -1.93 | ||||||||
| Working Capital Days | ||||||||||
| Receivable Days | 68.30 | 65.30 | ||||||||
| Inventory Days | 23.40 | 24.20 | ||||||||
| Payable Days | 176.70 | 99.90 | ||||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Clinitech Laboratory Ltd FAQs
The current trading price of Clinitech Laboratory on 07-Oct-2026 16:59 is ₹32.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-Oct-2026 the market cap of Clinitech Laboratory stood at ₹7.30 Cr
The latest P/E ratio of Clinitech Laboratory as of 06-Oct-2026 is 17.27.
The latest P/B ratio of Clinitech Laboratory as of 06-Oct-2026 is 0.79.
The 52-week high of Clinitech Laboratory is ₹47.15 and the 52-week low is ₹28.55.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Clinitech Laboratory is ₹9.47 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Clinitech Laboratory Ltd is a below average quality company.
The key valuation ratios of Clinitech Laboratory Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Clinitech Laboratory Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Clinitech Laboratory Ltd
The company was incorporated as Clinitech Laboratory Private Limited on March 19, 2010 under the Companies Act, 1956 with the Registrar of Companies, Mumbai. The status of the company was changed to public limited and the name of the company was changed to Clinitech Laboratory Limited vide Special Resolution dated July 24, 2023 pursuant to conversion of the Company into public limited Company. The fresh certificate of incorporation consequent to conversion was issued on August 25, 2023 by the Registrar of Companies, Mumbai.
The company is a provider of diagnostic and healthcare tests and services through chain of several diagnostic centers in and around Thane and Navi Mumbai. Its Promoters have many years of experience in diagnostic business. It conducts lakhs of tests per year in its NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited labs equipped with modern technology and high-end equipment. It conducts various tests at its centres which are classified under various heads as under: Biochemistry tests; Immunology tests; Hematology tests; Molecular Biology tests; Serology tests; Microbiology tests; and Histopathology tests.
Business area of the company
The company is one of the most trusted diagnostic centers & pathology labs.
Major Events and Milestones
- 2010: Incorporation of the company.
- 2012: Established new Lab at Kalyan.
- 2016: NABL Accreditation at Airoli Centre.
- 2018: Established new Lab at Thane.
- 2021: NABL Accreditation for SARS-COV-2 testing.
- 2021: Signed up agreements for Diagnostic Centre at Kharghar.
- 2022: Signed up agreements for Diagnostic Centre at Panvel / Badlapur.
- 2023: Converted Company to Limited.
- 2023: Established new Lab at Murbad and Panvel.
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
